Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
JD HEALTH
06618
5
KUAISHOU-W
01024
| (Q6)Jun 30, 2025 | (FY)Dec 31, 2024 | (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 12.34%1.82B | 23.93%3.34B | 28.57%1.62B | 29.27%2.7B | 29.83%1.26B | 25.17%2.09B | 20.49%971.19M | 39.53%1.67B | 44.58%806M | 22.10%1.19B |
| Operating income | 12.34%1.82B | 23.93%3.34B | 28.57%1.62B | 29.27%2.7B | 29.83%1.26B | 25.17%2.09B | 20.49%971.19M | 39.53%1.67B | 44.58%806M | 22.10%1.19B |
| Cost of sales | 15.29%-481.62M | -0.64%-1.05B | -12.17%-568.55M | -15.79%-1.04B | -8.35%-506.86M | -66.02%-898.06M | -71.20%-467.8M | -35.19%-540.94M | -35.45%-273.25M | -43.64%-400.15M |
| Operating expenses | 15.29%-481.62M | -0.64%-1.05B | -12.17%-568.55M | -15.79%-1.04B | -8.35%-506.86M | -66.02%-898.06M | -71.20%-467.8M | -35.19%-540.94M | -35.45%-273.25M | -43.64%-400.15M |
| Gross profit | 27.26%1.34B | 38.55%2.29B | 39.60%1.05B | 39.47%1.66B | 49.79%754.02M | 5.53%1.19B | -5.51%503.39M | 41.72%1.13B | 49.76%532.76M | 13.53%793.87M |
| Selling expenses | -43.13%-293.37M | -12.89%-483.4M | 7.50%-204.97M | -6.22%-428.19M | -21.27%-221.6M | -3.10%-403.12M | 2.93%-182.74M | -35.99%-390.98M | -39.89%-188.25M | 11.93%-287.52M |
| Administrative expenses | -23.21%-218.8M | -32.89%-399.89M | -23.23%-177.58M | -10.69%-300.92M | -5.69%-144.11M | -2.59%-271.85M | -8.02%-136.34M | -28.70%-264.99M | -24.95%-126.22M | 17.91%-205.9M |
| Research and development expenses | -6.13%-451.35M | -43.31%-910.7M | -44.52%-425.27M | -8.38%-635.48M | -10.84%-294.26M | -7.49%-586.37M | -2.32%-265.49M | -34.95%-545.49M | -38.00%-259.46M | 19.25%-404.21M |
| Impairment and provision | -126.26%-17.2M | 577.81%636.81M | -63.04%65.51M | 122.07%93.95M | 156.09%177.25M | -71.13%-425.7M | -149.55%-315.98M | -4,855.28%-248.76M | -5,123.68%-126.62M | -74.18%-5.02M |
| -Impairment of intangible assets | ---- | ---- | ---- | -30.98%-155.27M | ---- | 47.92%-118.54M | ---- | ---227.62M | ---- | ---- |
| -Other impairment is provision | -126.26%-17.2M | 155.52%636.81M | -63.04%65.51M | 181.14%249.22M | 156.09%177.25M | -1,353.52%-307.16M | -149.55%-315.98M | -320.96%-21.13M | -5,123.68%-126.62M | -74.18%-5.02M |
| Special items of operating profit | 116.39%20.47M | -4,402.81%-364.84M | 116.22%9.46M | -98.72%8.48M | -143.10%-58.32M | 111.70%660.07M | 163.51%135.31M | 708.60%311.8M | 73.02%51.35M | 1,892.76%38.56M |
| Operating profit | 18.62%379.32M | 96.13%772.19M | 50.14%319.76M | 145.60%393.72M | 181.33%212.98M | 1,302.08%160.31M | -124.90%-261.86M | 81.01%-13.34M | -186.75%-116.44M | 81.50%-70.22M |
| Financing income | 56.36%37.36M | 14.20%50.66M | 1.35%23.9M | 197.34%44.37M | 468.83%23.58M | 521.45%14.92M | 236.17%4.15M | -91.88%2.4M | -94.30%1.23M | -35.30%29.56M |
| Special items of earning before tax | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 472.02%4.56M |
| Earning before tax | 21.25%416.68M | 87.83%822.85M | 45.27%343.66M | 150.01%438.09M | 191.79%236.56M | 1,702.47%175.23M | -123.71%-257.71M | 69.71%-10.94M | -557.77%-115.2M | 89.23%-36.1M |
| Tax | 6.26%-37.44M | 76.71%-16.69M | -47.43%-39.94M | 54.16%-71.67M | -13.34%-27.09M | -135.11%-156.34M | -6.33%-23.9M | -176.74%-66.5M | -200.53%-22.48M | -167.45%-24.03M |
| After-tax profit from continuing operations | 24.87%379.24M | 120.01%806.16M | 45.00%303.72M | 1,839.64%366.42M | 174.38%209.47M | 124.40%18.89M | -104.54%-281.61M | -28.77%-77.43M | -450.87%-137.68M | 82.52%-60.13M |
| Earning after tax | 24.87%379.24M | 120.01%806.16M | 45.00%303.72M | 1,839.64%366.42M | 174.38%209.47M | 124.40%18.89M | -104.54%-281.61M | -28.77%-77.43M | -450.87%-137.68M | 85.15%-60.13M |
| Minority profit | -6,166.89%-17.78M | 108.29%984K | 101.61%293K | 84.22%-11.88M | -18.15%-18.16M | -128.62%-75.25M | -70.51%-15.37M | -71.78%-32.92M | 0.30%-9.01M | -130.92%-19.16M |
| Shareholders should account for profits from continuing business | ---- | 120.01%806.16M | ---- | --366.42M | ---- | ---- | ---- | ---- | ---- | ---- |
| Profit attributable to shareholders | 30.84%397.02M | 112.84%805.18M | 33.30%303.43M | 301.83%378.29M | 185.50%227.63M | 311.49%94.14M | -106.93%-266.25M | -8.65%-44.51M | -706.53%-128.67M | 89.67%-40.97M |
| Basic earnings per share | 28.57%0.09 | 100.00%0.18 | 40.00%0.07 | 350.00%0.09 | 183.33%0.05 | 300.00%0.02 | -100.00%-0.06 | 0.00%-0.01 | -650.00%-0.03 | 88.89%-0.01 |
| Diluted earnings per share | 33.33%0.08 | 125.00%0.18 | 20.00%0.06 | 300.00%0.08 | 183.33%0.05 | 300.00%0.02 | -100.00%-0.06 | 0.00%-0.01 | -650.00%-0.03 | 88.89%-0.01 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
| Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
| Auditor | -- | PricewaterhouseCoopers | -- | PricewaterhouseCoopers | -- | PricewaterhouseCoopers | -- | PricewaterhouseCoopers | -- | PricewaterhouseCoopers |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.